Steve S Sommer

This inventor holds 19 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents, primarily in Nucleic Acid Amplification. Top assignees: Beckman Research Institute, City of Hope, Baylor College of Medicine. Active years: 2001-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steve S Sommer. Retrieved from https://idiyas.com/inventor/steve-s-sommer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 1)

% Patents Active = 57.9

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 96(Granted Patents)

Company Filing History:

19 out of 692

Beckman Research Institute, City of Hope

patents

1 out of 621

Baylor College of Medicine

patents

where one patent can have more than one assignee

Years Active: 2001-2018

Loading Chart...

Areas of Expertise:

Nucleic Acid Amplification

Mutation Detection

Polymerization Methods

Gel Electrophoresis

PCR Assay

Micro RNAs

Transplantation Failure

Dystrophin Gene

Neurexin Variants

Chromosomal Mutations

SSCP

Allele-Specific Amplification

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10072294 - Ultra-high sensitive monitoring of early transplantation failure (2018-09-11),

2. 8252534 - Micro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders (2012-08-28),

3. 8173371 - Serial coupling of nucleic acid metabolism and extension for nucleic acid amplification (2012-05-08),

4. 7919253 - Serial coupling of nucleic acid metabolism and extension for nucleic acid amplification (2011-04-05),

5. 7914995 - Reaction mixture for pyrophosphorolysis activated polymerization (PAP) (2011-03-29),

6. 7871820 - High frequency of neurexin 1β signal peptide structural variants in patients with autism (2011-01-18),

7. 7504221 - Pyrophosphorolysis activated polymerization (PAP) (2009-03-17),

8. 7449561 - Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy (2008-11-11),

9. 7238480 - Pyrophosphorolysis activated polymerization (PAP) (2007-07-03),

10. 7141153 - pK-matched running buffers for gel electrophoresis (2006-11-28),

11. 7105298 - Serial coupling of restriction cleavage and extension for nucleic acid amplification (2006-09-12),

12. 7033763 - Pyrophosphorolysis activated polymerization (PAP) (2006-04-25),

13. 6582574 - pK-matched running buffers for gel electrophoresis (2003-06-24),

14. 6534269 - Pyrophosphorolysis activated polymerization (PAP): application to allele-specific amplification and nucleic acid sequence determination (2003-03-18),

15. 6376193 - Method for detecting mutations in nucleic acids (2002-04-23),

Title: **Innovator Spotlight: Steve S. Sommer**

Introduction

Steve S. Sommer is a distinguished inventor based in Duarte, California, recognized for his significant contributions to the fields of transplantation and neuropsychiatric disorders. With an impressive portfolio of 19 patents, Sommer has made substantial advancements that aim to enhance medical diagnostics and treatment methodologies.

Latest Patents

Two of his latest inventions showcase his innovative approach to addressing critical medical challenges. The first patent pertains to the **Ultra-high sensitivity monitoring of early transplantation failure**. This invention introduces a method that detects transplantation failure of a transplanted organ or cells by identifying a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. This method stands out for its exceptional sensitivity, specificity, and selectivity, allowing for the early detection of transplantation failures, which in turn facilitates timely treatment interventions.

The second patent focuses on **Micro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders**. This invention outlines a method for diagnosing, assessing susceptibility, and treating schizophrenia through the identification and observation of specific microRNAs (miRNA) and their variants. Sommer’s research has identified microRNA alleles associated with these disorders and highlights the potential for using miRNAs to select preferred therapies for individuals at risk of or suffering from schizophrenia or psychosis.

Career Highlights

Throughout his career, Steve S. Sommer has held pivotal positions in reputable organizations. He has worked with the City of Hope and Baylor College of Medicine, both of which are renowned for their contributions to medical research and treatment. His extensive experience in these institutions has fostered significant advancements in understanding complex health issues and developing innovative solutions.

Collaborations

Steve’s work is often enriched by collaboration with esteemed colleagues, including Qiang Liu and Arthur D. Riggs. These partnerships illustrate the collaborative spirit inherent in the scientific community, driving forward innovation and contributing to meaningful advancements in healthcare.

Conclusion

Steve S. Sommer's contributions to patentable inventions reflect a commitment to enhancing medical technology and improving patient outcomes. Through his innovative approaches, Sommer continues to influence the landscape of medical diagnostics and treatments, showcasing the vital role inventors play in shaping the future of healthcare.

Profile summary based on public USPTO records.